Bitcoin is on the rise again. Here’s why Warren Buffett remains a crypto hater
CNBC: Investing
OCTOBER 22, 2023
The Oracle of Omaha famously believes cryptocurrencies are highly speculative, non-productive assets.
Sun.Oct 22, 2023
143 
Della Kirkman, CPA interviews They Got Acquired Founder, Alexis Grant, Shares Insights on Building and Selling Online Businesses
How2Exit
OCTOBER 22, 2023
b' E151: Della Kirkman, CPA interviews They Got Acquired Founder, Alexis Grant, Shares Insights on Building and Selling Online Businesses - Watch Here rn rn Here is what my team and I learned from this interview: (These are notes from team members, writers, sometimes AI, and even listeners who submitted what i learned loosely edited and shared here) - If it seems a bit unrefined, you're reading our notes, so. yeah.
Join 38,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Top Wall Street analysts favor these five dividend stocks during tumultuous times
CNBC: Investing
OCTOBER 22, 2023
TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy.
Textainer to be Acquired by Stonepeak for $7.4 Billion
Global Newswire by Notified: M&A
OCTOBER 22, 2023
Textainer Shareholders to Receive $50.00 Per Share in Cash Textainer Shareholders to Receive $50.
15 Modern Use Cases for Enterprise Business Intelligence
Advertisement
Large enterprises face unique challenges in optimizing their Business Intelligence (BI) output due to the sheer scale and complexity of their operations. Unlike smaller organizations, where basic BI features and simple dashboards might suffice, enterprises must manage vast amounts of data from diverse sources. What are the top modern BI use cases for enterprise businesses to help you get a leg up on the competition?
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
CNBC: Investing
OCTOBER 22, 2023
Piper Sandler analyst Allison Bratzel said the loss of lean muscle while taking GLP-1 drugs is "a major shortcoming" that could have bigger consequences.
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
Global Newswire by Notified: M&A
OCTOBER 22, 2023
BASEL, Switzerland and LONDON and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the entry into a definitive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody.
Let's personalize your content